Short Interest in Daxor Corporation (NASDAQ:DXR) Drops By 44.0%

Daxor Corporation (NASDAQ:DXR) was the target of a large decrease in short interest during the month of February. As of February 13th, there was short interest totaling 3,761 shares, a decrease of 44.0% from the January 29th total of 6,713 shares. Currently, 0.2% of the shares of the stock are sold short. Based on an average daily volume of 6,480 shares, the short-interest ratio is presently 0.6 days. Based on an average daily volume of 6,480 shares, the short-interest ratio is presently 0.6 days. Currently, 0.2% of the shares of the stock are sold short.

Daxor Stock Down 0.8%

Shares of DXR opened at $11.86 on Friday. The stock’s 50-day moving average price is $13.10 and its two-hundred day moving average price is $12.63. Daxor has a 12 month low of $7.10 and a 12 month high of $14.76.

Analyst Ratings Changes

A number of analysts have weighed in on DXR shares. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Daxor in a research note on Monday, December 29th. Lake Street Capital started coverage on Daxor in a report on Wednesday, February 11th. They set a “buy” rating on the stock. Two investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $25.00.

Hedge Funds Weigh In On Daxor

An institutional investor recently bought a new position in Daxor stock. Nano Cap New Millennium Growth Fund L P purchased a new stake in shares of Daxor Corporation (NASDAQ:DXR) during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 12,500 shares of the company’s stock, valued at approximately $184,000. Nano Cap New Millennium Growth Fund L P owned about 0.25% of Daxor at the end of the most recent quarter. Institutional investors and hedge funds own 1.34% of the company’s stock.

Daxor Company Profile

Daxor Corporation is a medical diagnostics company focused on providing precise blood volume analysis to support patient management in critical care, surgical, cardiology and nephrology settings. The company’s core offering, the BVA‐100 Blood Volume Analyzer, employs radiolabeled albumin techniques to deliver accurate measurements of total blood volume, red cell mass and plasma volume. By quantifying a patient’s fluid status, Daxor aims to help clinicians tailor therapies for conditions such as anemia, heart failure and fluid overload.

In addition to the BVA‐100 analyzer, Daxor supplies reagent kits, calibration standards and software for data analysis and reporting.